Table 2.
Effect of CHF 4227 on fibrinogen concentrations after 4 weeks of treatment. Baseline, day 29 values, absolute and % changes from baseline (mean ± SEM), least square means (LSM) of the difference from placebo and its 95% confidence intervals (95% CI) are reported
| CHF 4227 dose | ||||||
|---|---|---|---|---|---|---|
| Fibrinogen (g l−1) | 5 mg | 10 mg | 25 mg | 50 mg | 100 mg | Placebo |
| Baseline | 3.30 ± 0.24 | 3.31 ± 0.15 | 3.38 ± 0.19 | 3.51 ± 0.15 | 3.66 ± 0.24 | 3.45 ± 0.16 |
| Day 29 | 2.96 ± 0.18** | 3.00 ± 0.13* | 3.51 ± 0.23 | 3.28 ± 0.14 | 3.62 ± 0.26 | 3.69 ± 0.11 |
| Absolute change | −0.34 ± 0.13 | −0.31 ± 0.13 | 0.10 ± 0.15 | −0.24 ± 0.12 | 0.05 ± 0.42 | 0.17 ± 0.14 |
| % change | −9.14 ± 3.61 | −8.84 ± 4.19 | 3.31 ± 4.06 | −6.31 ± 3.70 | 3.11 ± 11.03 | 6.67 ± 4.59 |
| LSM difference | −0.73** | −0.69* | −0.18 | −0.42 | −0.07 | |
| 95% CI | −1.32, −0.14 | −1.31, −0.08 | −0.75, 0.39 | −1.00, 0.17 | −0.76, 0.62 | |
*, **
Statistically significant difference between active and placebo, P < 0.05 and P < 0.01, respectively, Dunnett's test.